Bartlett & CO. Wealth Management LLC Boosts Stock Position in Medpace Holdings, Inc. $MEDP

Bartlett & CO. Wealth Management LLC lifted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 441.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,581 shares of the company’s stock after purchasing an additional 1,289 shares during the quarter. Bartlett & CO. Wealth Management LLC’s holdings in Medpace were worth $888,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Jackson Thornton Wealth Management LLC boosted its holdings in shares of Medpace by 8.6% in the 4th quarter. Jackson Thornton Wealth Management LLC now owns 1,193 shares of the company’s stock worth $726,000 after purchasing an additional 94 shares in the last quarter. Azzad Asset Management Inc. ADV purchased a new stake in shares of Medpace in the 4th quarter valued at $564,000. Portside Wealth Group LLC boosted its stake in shares of Medpace by 2.9% in the 4th quarter. Portside Wealth Group LLC now owns 1,106 shares of the company’s stock valued at $621,000 after purchasing an additional 31 shares in the last quarter. eCIO Inc. purchased a new stake in shares of Medpace in the 4th quarter valued at $66,000. Finally, Ascent Group LLC boosted its stake in shares of Medpace by 6.1% in the 4th quarter. Ascent Group LLC now owns 18,387 shares of the company’s stock valued at $10,327,000 after purchasing an additional 1,056 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MEDP. Truist Financial cut their price objective on shares of Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research note on Wednesday, February 11th. Mizuho set a $582.00 price objective on shares of Medpace in a research note on Wednesday, February 11th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and dropped their target price for the company from $462.00 to $419.00 in a report on Wednesday, February 18th. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price for the company in a report on Friday, February 13th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $486.67.

More Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Recent fundamentals remain a tailwind: Medpace reported a strong quarter on Feb. 9 (EPS and revenue above expectations, ~32% revenue growth year/year) and provided FY2026 EPS guidance (16.680–17.500). Those results support the company’s premium valuation and longer‑term growth thesis.
• Neutral Sentiment: Short‑interest data for April appears to show 0 shares (0.0 days), which looks like either no material shorting or a data/reporting anomaly — this item does not explain today’s move.
• Negative Sentiment: Multiple national law firms have announced a securities class action (alleged violations covering purchases between Apr 22, 2025 and Feb 9, 2026) and are soliciting lead plaintiffs with early‑June deadlines — this raises litigation risk, potential future settlements or defense costs, and near‑term investor uncertainty, pressuring the share price. Medpace Holdings Inc. (MEDP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit MEDP Investors Have Opportunity to Lead Medpace Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm Glancy Prongay Wolke & Rotter LLP Encourages Medpace Shareholders To Inquire About Securities Fraud Class Action

Medpace Stock Performance

NASDAQ MEDP opened at $493.53 on Monday. The stock has a 50 day simple moving average of $472.89 and a two-hundred day simple moving average of $537.71. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The stock has a market cap of $14.10 billion, a P/E ratio of 32.26, a price-to-earnings-growth ratio of 2.37 and a beta of 1.39.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million during the quarter, compared to analysts’ expectations of $689.53 million. During the same period last year, the company posted $3.67 EPS. The company’s quarterly revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.